Published in Lung Cancer on June 01, 2004
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol (2011) 1.40
Thymomas: review of current clinical practice. Ann Thorac Surg (2009) 1.21
Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive. Front Oncol (2014) 1.06
Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol (2014) 1.02
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res (2014) 0.98
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer (2009) 0.91
Pleuropneumonectomy for a large thymoma with multiple pleural dissemination using median sternotomy followed by posterolateral thoracotomy. Surg Case Rep (2015) 0.87
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer (2010) 0.83
Thymic neoplasm: a rare disease with a complex clinical presentation. J Thorac Dis (2013) 0.83
Prognosis and therapeutic response according to the World Health Organization histological classification in advanced thymoma. Surg Today (2011) 0.81
Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study. Am J Clin Oncol (2016) 0.81
Pediatric thymomas: report of two cases and comprehensive review of the literature. Pediatr Surg Int (2013) 0.81
Surgical Approaches for Stage IVA Thymic Epithelial Tumors. Front Oncol (2014) 0.81
En bloc extended total thymectomy and extrapleural pneumonectomy in Masaoka stage IVA thymomas. J Cardiothorac Surg (2011) 0.81
Pretreatment biopsy for histological diagnosis and induction therapy in thymic tumors. J Thorac Dis (2016) 0.80
Radiotherapy for thymic neoplasms. J Thorac Oncol (2010) 0.80
Management of metastatic malignant thymoma with advanced radiation and chemotherapy techniques: report of a rare case. World J Surg Oncol (2015) 0.79
CT staging and preoperative assessment of resectability for thymic epithelial tumors. J Thorac Dis (2016) 0.78
Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis (2011) 0.76
Multimodality therapy for locally-advanced thymic epithelial tumors: where are we now? J Thorac Dis (2016) 0.75
Surgical outcomes and reevaluation of treatment strategies for thymomas. Oncol Lett (2010) 0.75
Pretreatment biopsy for thymic epithelial tumors-does histology subtype matter for treatment strategy? J Thorac Dis (2016) 0.75
Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge. J Radiat Oncol (2015) 0.75
Efficacy of computed tomography features in predicting stage III thymic tumors. Oncol Lett (2016) 0.75
How large databases may impact clinical practices for rare tumors-postoperative chemotherapy in thymic malignancies. J Thorac Dis (2016) 0.75
Non-surgical treatment of locally advanced thymic epithelial tumors-a need for multicenter trials. J Thorac Dis (2016) 0.75
The spectrum of ectopic thymomas. Virchows Arch (2016) 0.75
[Thymus cancers : A clinical observation]. Pathologe (2016) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst (2011) 5.79
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Recent advances in head and neck cancer. N Engl J Med (2008) 5.05
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Management of primary pulmonary artery sarcomas. Ann Thorac Surg (2009) 3.37
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys (2005) 3.05
Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases. Am J Surg Pathol (2002) 3.03
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol (2006) 2.92
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 2.90
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys (2006) 2.82
4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys (2007) 2.80
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol (2011) 2.70
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol (2003) 2.69
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2010) 2.69
Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg (2004) 2.62
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med (2008) 2.48
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther (2006) 2.38
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys (2007) 2.35
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg (2010) 2.31
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 2.28
A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano (2010) 2.27
Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol (2013) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol (2013) 2.22
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 2.22
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
Predicting lung cancer prior to surgical resection in patients with lung nodules. J Thorac Oncol (2014) 2.17
Obesity increases operating room time for lobectomy in the society of thoracic surgeons database. Ann Thorac Surg (2012) 2.16
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol (2002) 2.15
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg (2013) 2.15
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.12
Focus on head and neck cancer. Cancer Cell (2004) 2.11
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys (2009) 2.08
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer (2005) 2.04
Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys (2013) 2.02
Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg (2007) 2.01
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol (2011) 1.99
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol (2005) 1.98
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 1.97
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94